Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
Daniel Y Lu, Andrew Adelsheimer, Kevin Chan...
https://pubmed.ncbi.nlm.nih.gov/34114302/Actively Recruiting
Led by Fondazione GISE Onlus · Updated on 2025-07-01
786
Participants Needed
16
Research Sites
4 weeks
Total Duration
Researchers are evaluating a cardiogenic shock protocol designed to improve communication and collaboration among hospitals to timely refer cardiogenic shock patients from spoke to hub centres in the Turin and Milan metropolitan areas. This observational study includes both a retrospective cohort from 2016 to 2019 and a prospective cohort starting in 2024. The purpose is to assess whether implementing this dedicated protocol reduces in-hospital or 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock AMICS. Cardiogenic shock is a critical condition requiring rapid intervention and specialized care, and the study focuses on improving outcomes by optimizing patient transfer and treatment coordination. The study compares two groups one retrospective group of patients admitted before the protocol was implemented, and one prospective group admitted after the protocol adoption. Patients in the prospective cohort are managed under a standardized communication and referral protocol between spoke and hub centres, which include advanced cardiac interventions such as percutaneous mechanical circulatory support and prompt transfer to specialized teams. Hub centres have multidisciplinary shock teams, cardiac surgery backup, and 247 availability of cardiac care services. Spoke centres provide initial care and stabilization. The study involves 16 centres, with four hubs each receiving patients from three spoke centres. Participants will be monitored during their hospital stay and followed up to 30 days from admission. Data collected include clinical characteristics, treatments, timing of mechanical support device insertion, adverse events, and outcomes like mortality, stroke, bleeding, renal replacement therapy, vascular complications, and myocardial infarction. The study uses electronic health records and prospectively collected data, with no changes to standard care. The primary measure is 30-day mortality, and secondary outcomes include various clinical events and timing metrics related to treatment support. The study aims to provide insight into whether the hub-and-spoke protocol improves survival and quality of care for cardiogenic shock patients.
CONDITIONS
Pilot Italian Cardiogenic Shock Initiative
A
Alaide Chieffo, Prof
M
Mario Iannaccone, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione GISE Onlus
Lead Sponsor
Mediolanum Cardio Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days from hospital admission
Participants admitted with cardiogenic shock are observed and managed according to the hub and spoke network protocol, including communication between spoke and hub centers for timely referral and transfer.
Visits and assessments during hospital stay and up to 30 days follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Daniel Y Lu, Andrew Adelsheimer, Kevin Chan...
https://pubmed.ncbi.nlm.nih.gov/34114302/Borja Ibanez, Stefan James, Stefan Agewall...
https://pubmed.ncbi.nlm.nih.gov/28886621/Takahito Nasu, Ryo Ninomiya, Yorihiko Koeda...
https://pubmed.ncbi.nlm.nih.gov/38048601/Dagmar M Ouweneel, Erlend Eriksen, Krischan D Sjauw...
https://pubmed.ncbi.nlm.nih.gov/27810347/Theresa A McDonagh, Marco Metra, Marianna Adamo...
https://pubmed.ncbi.nlm.nih.gov/34447992/Mario Iannaccone, Stefano Albani, Francesco Giannini...
https://pubmed.ncbi.nlm.nih.gov/32971148/Dhaval Kolte, Sahil Khera, Wilbert S Aronow...
https://pubmed.ncbi.nlm.nih.gov/24419737/Behnam N Tehrani, Matthew W Sherwood, Carolyn Rosner...
https://pubmed.ncbi.nlm.nih.gov/36175063/J S Hochman, L A Sleeper, J G Webb...
https://pubmed.ncbi.nlm.nih.gov/10460813/Mario Iannaccone, Luca Franchin, Ivan D Hanson...
https://pubmed.ncbi.nlm.nih.gov/35533755/Fondazione GISE Onlus
Lead Sponsor
Mediolanum Cardio Research
Collaborating Sponsor